Protectif Deep Tint
Zinc Oxide And Titanium Dioxide
Derma Research Group Inc.
Human Otc Drug
NDC 82038-002Protectif Deep Tint also known as Zinc Oxide And Titanium Dioxide is a human otc drug labeled by 'Derma Research Group Inc.'. National Drug Code (NDC) number for Protectif Deep Tint is 82038-002. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Protectif Deep Tint drug includes Titanium Dioxide - 6.5 g/100g Zinc Oxide - 8.6 g/100g . The currest status of Protectif Deep Tint drug is Active.
Drug Information:
| Drug NDC: | 82038-002 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Protectif Deep Tint |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Zinc Oxide And Titanium Dioxide |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Derma Research Group Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Cream |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | TITANIUM DIOXIDE - 6.5 g/100g
ZINC OXIDE - 8.6 g/100g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 21 Jun, 2022 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 04 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | M020 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Derma Research Group Inc.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | 15FIX9V2JP
SOI2LOH54Z
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 82038-002-02 | 1 TUBE in 1 CARTON (82038-002-02) / 100 g in 1 TUBE (82038-002-01) | 21 Jun, 2022 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose sun protectant
Product Elements:
Protectif deep tint zinc oxide and titanium dioxide dipropylene glycol apple ethylhexylglycerin cyclotetrapeptide-24 aminocyclohexane carboxylate lecithin, soybean ferrosoferric oxide vinyl dimethicone/methicone silsesquioxane crosspolymer .alpha.-tocopherol acetate pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate) silica dimethyl silylate cetyl peg/ppg-10/1 dimethicone (hlb 4) polyethylene glycol 400 alcohol polysorbate 20 sodium chloride sorbitan olivate isomalt green tea leaf arabica coffee bean triethoxycaprylylsilane ferric oxide red ferric oxide yellow dimethicone cyclomethicone 4 hydroxytyrosol benzoic acid hyaluronate sodium cyclomethicone 6 ascorbyl palmitate sodium ferrocyanide decahydrate potassium sorbate cetearyl olivate citric acid monohydrate phenoxyethanol peg/ppg-18/18 dimethicone polyglyceryl-4 isostearate hexyl laurate ectoine alkyl (c12-15) benzoate glycerin aluminum hydroxide sodium citrate dimethicone/polyglycerin-3 crosspolymer ethylhexyl palmitate pentylene glycol hexylene glycol dimethicone/peg-10/15 crosspolymer ascorbic acid polygonum aviculare top sodium benzoate carbomer homopolymer, unspecified type vitis vinifera stem caprylyl glycol dimethicone/vinyl dimethicone crosspolymer (soft particle) water polyglyceryl-3 polydimethylsiloxyethyl dimethicone (4000 mpa.s) tocopherol cyclomethicone 5 stearic acid butylene glycol triethoxysilylethyl polydimethylsiloxyethyl hexyl dimethicone palmitoyl tripeptide-1 palmitoyl tetrapeptide-7 titanium dioxide titanium dioxide zinc oxide zinc oxide
Indications and Usage:
Uses helps prevent sunburn
Warnings:
Warning for external use only.
Do Not Use:
Warning for external use only.
When Using:
When using this product, avoid contect with eyes.if contect occurs, rinse throughly with water.
Dosage and Administration:
Directions: apply 15 minutes before sun exposure reapply at least every 2 hours sun protection measures spending time in the sun increases your risk of skin cancer and early skin aging to decrease this risk regularly use a sunscreen with a broad spectrum spf value of 15 or higher and other sun protection measures including limit time in the sun especially from 10 am to 2 pm wear long sleeve shirts pants hats and sunglasses
Stop Use:
Stop use discontinue use if rash or irritation develops or lasts. if irritation persists,consultant a doctor
Package Label Principal Display Panel:
Protectifdeeptint